The Medicines Company Acquires Targanta

The Medicines Company Acquires Targanta

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

WilmerHale client, The Medicines Company, announced yesterday that it had completed its acquisition of Targanta Therapeutics Corporation.

The Medicines Company completed the transaction through a cash tender offer followed by a short form merger. The Medicines Company paid Targanta stockholders $2.00 per share, net to the seller in cash, plus the contractual right to receive up to an additional $4.55 per share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.

With the consummation of the acquisition, Targanta has become a wholly owned subsidiary of The Medicines Company. Further details can be found by clicking here.

WilmerHale was legal advisor to The Medicines Company in this transaction, with a team including: partners David Redlick, Hal Leibowitz, Stuart Falber and Jeffrey Hermanson; counsels Marisa Murtagh and Jessica Lopez; and associates Dana Krueger and Erica Koenig.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel